Market-Based Licensing for HPV Vaccines in Developing Countries

While HPV vaccines hold great promise for preventing cervical cancer, 93% of related mortality occurs in low- and middle-income countries where high costs limit access, and existing mechanisms like differential pricing and advance market commitments have had only partial success. The authors propose a new licensing model that would leverage generic competition to lower prices in these countries while still ensuring pharmaceutical manufacturers receive appropriate returns on their research and development investments.